vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and Emerson Electric (EMR). Click either name above to swap in a different company.
Emerson Electric is the larger business by last-quarter revenue ($4.3B vs $2.8B, roughly 1.6× Bausch Health Companies Inc.). Emerson Electric runs the higher net margin — 13.9% vs -3.7%, a 17.6% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs 4.1%). Emerson Electric produced more free cash flow last quarter ($602.0M vs $403.0M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs -0.3%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Emerson ElectricEMREarnings & Financial Report
Emerson Electric Co. is an American multinational corporation headquartered in St. Louis, Missouri. The Fortune 500 company delivers a range of engineering services, manufactures industrial automation equipment, climate control systems, and precision measurement instruments, and provides software engineering for industrial, commercial, and consumer markets.
BHC vs EMR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $4.3B |
| Net Profit | $-103.0M | $605.0M |
| Gross Margin | — | 53.2% |
| Operating Margin | 17.0% | 17.8% |
| Net Margin | -3.7% | 13.9% |
| Revenue YoY | 9.3% | 4.1% |
| Net Profit YoY | -205.1% | 3.4% |
| EPS (diluted) | $-0.30 | $1.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $4.3B | ||
| Q3 25 | $2.7B | $4.9B | ||
| Q2 25 | $2.5B | $4.6B | ||
| Q1 25 | $2.3B | $4.4B | ||
| Q4 24 | $2.6B | $4.2B | ||
| Q3 24 | $2.5B | $4.6B | ||
| Q2 24 | $2.4B | $4.4B | ||
| Q1 24 | $2.2B | $4.4B |
| Q4 25 | $-103.0M | $605.0M | ||
| Q3 25 | $179.0M | $637.0M | ||
| Q2 25 | $148.0M | $586.0M | ||
| Q1 25 | $-58.0M | $485.0M | ||
| Q4 24 | $98.0M | $585.0M | ||
| Q3 24 | $-85.0M | $996.0M | ||
| Q2 24 | $10.0M | $329.0M | ||
| Q1 24 | $-64.0M | $501.0M |
| Q4 25 | — | 53.2% | ||
| Q3 25 | — | 51.9% | ||
| Q2 25 | — | 52.6% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 53.5% | ||
| Q3 24 | — | 51.3% | ||
| Q2 24 | — | 52.8% | ||
| Q1 24 | — | 52.2% |
| Q4 25 | 17.0% | 17.8% | ||
| Q3 25 | 23.1% | 16.4% | ||
| Q2 25 | 17.5% | 16.1% | ||
| Q1 25 | 12.2% | 14.2% | ||
| Q4 24 | 21.8% | 18.6% | ||
| Q3 24 | 12.7% | 14.7% | ||
| Q2 24 | 16.2% | 10.4% | ||
| Q1 24 | 13.1% | 16.2% |
| Q4 25 | -3.7% | 13.9% | ||
| Q3 25 | 6.7% | 13.1% | ||
| Q2 25 | 5.8% | 12.9% | ||
| Q1 25 | -2.6% | 10.9% | ||
| Q4 24 | 3.8% | 14.0% | ||
| Q3 24 | -3.4% | 21.6% | ||
| Q2 24 | 0.4% | 7.5% | ||
| Q1 24 | -3.0% | 11.4% |
| Q4 25 | $-0.30 | $1.07 | ||
| Q3 25 | $0.48 | $1.12 | ||
| Q2 25 | $0.40 | $1.04 | ||
| Q1 25 | $-0.16 | $0.86 | ||
| Q4 24 | $0.24 | $1.02 | ||
| Q3 24 | $-0.23 | $1.74 | ||
| Q2 24 | $0.03 | $0.57 | ||
| Q1 24 | $-0.17 | $0.87 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | — |
| Total DebtLower is stronger | $20.8B | $7.6B |
| Stockholders' EquityBook value | $-554.0M | $20.3B |
| Total Assets | $26.4B | $41.9B |
| Debt / EquityLower = less leverage | — | 0.37× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | — | ||
| Q3 24 | $719.0M | — | ||
| Q2 24 | $595.0M | — | ||
| Q1 24 | $733.0M | — |
| Q4 25 | $20.8B | $7.6B | ||
| Q3 25 | $21.0B | $8.9B | ||
| Q2 25 | $21.7B | $8.3B | ||
| Q1 25 | $21.5B | $8.2B | ||
| Q4 24 | $21.6B | $6.6B | ||
| Q3 24 | $21.5B | $7.7B | ||
| Q2 24 | $21.7B | $7.1B | ||
| Q1 24 | $22.1B | $7.6B |
| Q4 25 | $-554.0M | $20.3B | ||
| Q3 25 | $-565.0M | $20.3B | ||
| Q2 25 | $-764.0M | $19.9B | ||
| Q1 25 | $-1.2B | $19.2B | ||
| Q4 24 | $-1.3B | $20.5B | ||
| Q3 24 | $-1.2B | $21.6B | ||
| Q2 24 | $-1.2B | $20.8B | ||
| Q1 24 | $-1.1B | $20.9B |
| Q4 25 | $26.4B | $41.9B | ||
| Q3 25 | $26.8B | $42.0B | ||
| Q2 25 | $27.3B | $42.5B | ||
| Q1 25 | $26.4B | $42.0B | ||
| Q4 24 | $26.5B | $42.6B | ||
| Q3 24 | $26.5B | $44.2B | ||
| Q2 24 | $26.5B | $45.6B | ||
| Q1 24 | $26.9B | $46.4B |
| Q4 25 | — | 0.37× | ||
| Q3 25 | — | 0.44× | ||
| Q2 25 | — | 0.42× | ||
| Q1 25 | — | 0.42× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.36× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $699.0M |
| Free Cash FlowOCF − Capex | $403.0M | $602.0M |
| FCF MarginFCF / Revenue | 14.4% | 13.9% |
| Capex IntensityCapex / Revenue | 3.3% | 2.2% |
| Cash ConversionOCF / Net Profit | — | 1.16× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $4.4B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $699.0M | ||
| Q3 25 | $405.0M | $3.1B | ||
| Q2 25 | $289.0M | $1.1B | ||
| Q1 25 | $211.0M | $241.0M | ||
| Q4 24 | $601.0M | $777.0M | ||
| Q3 24 | $405.0M | $3.3B | ||
| Q2 24 | $380.0M | $1.1B | ||
| Q1 24 | $211.0M | $743.0M |
| Q4 25 | $403.0M | $602.0M | ||
| Q3 25 | $314.0M | $2.7B | ||
| Q2 25 | $190.0M | $977.0M | ||
| Q1 25 | $96.0M | $154.0M | ||
| Q4 24 | $495.0M | $694.0M | ||
| Q3 24 | $334.0M | $2.9B | ||
| Q2 24 | $302.0M | $998.0M | ||
| Q1 24 | $129.0M | $661.0M |
| Q4 25 | 14.4% | 13.9% | ||
| Q3 25 | 11.7% | 54.9% | ||
| Q2 25 | 7.5% | 21.5% | ||
| Q1 25 | 4.2% | 3.5% | ||
| Q4 24 | 19.3% | 16.6% | ||
| Q3 24 | 13.3% | 63.1% | ||
| Q2 24 | 12.6% | 22.8% | ||
| Q1 24 | 6.0% | 15.1% |
| Q4 25 | 3.3% | 2.2% | ||
| Q3 25 | 3.4% | 8.9% | ||
| Q2 25 | 3.9% | 2.0% | ||
| Q1 25 | 5.1% | 2.0% | ||
| Q4 24 | 4.1% | 2.0% | ||
| Q3 24 | 2.8% | 9.1% | ||
| Q2 24 | 3.2% | 2.1% | ||
| Q1 24 | 3.8% | 1.9% |
| Q4 25 | — | 1.16× | ||
| Q3 25 | 2.26× | 4.86× | ||
| Q2 25 | 1.95× | 1.83× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | 6.13× | 1.33× | ||
| Q3 24 | — | 3.35× | ||
| Q2 24 | 38.00× | 3.31× | ||
| Q1 24 | — | 1.48× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
EMR
| Other | $1.8B | 41% |
| Software And Systems | $1.0B | 24% |
| Intelligent Devices | $996.0M | 23% |
| Safety And Productivity | $503.0M | 12% |
